drugset
Drugs / sacubitril/valsartan
last change Mar 2020 re-read 2 minutes ago

sacubitril/valsartan

also known as LCZ696
Developed for
heart failure
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

today NCT02970669 · Ph 4
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02970669 Dec 2016 → Mar 2018 heart failure Novartis Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 4 releases

DateIssuerRelease
2020-03-02 Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan otsuka.co.jp ↗
2018-08-25 Novartis Pharmaceuticals Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2015-07-07 Novartis Pharmaceuticals Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization novartis.com ↗
2015-02-13 Novartis Pharmaceuticals Novartis' heart failure medicine LCZ696 granted FDA priority review novartis.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as sacubitril/valsartan ClinicalTrials.gov intervention name — accepted as the source's own label NCT02970669 ↗
Known as LCZ696 “sacubitril/valsartan (LCZ696)” NCT02970669 ↗
Route Oral “sacubitril/valsartan tablet taken orally.” NCT02970669 ↗